From menarche to menopause
Open Access
- 29 December 2020
- journal article
- Published by Publishing Office TRILIST in Reproductive Endocrinology
- No. 56,p. 18-22
- https://doi.org/10.18370/2309-4117.2020.56.18-22
Abstract
On September 11–12, 2020, in Kyiv hosted the International Women's Health Summit “From Menarche to Menopause” with the participation of leading foreign and domestic experts in the field of obstetrics and gynecology. The event was devoted to such topical topics as miscarriage, infertility, menstrual irregularities, menopausal hormone therapy (MHT).The current concern in clinical practice is not overuse of MHT, but it underutilization, and the fact that only a small number of women with impaired quality of life through menopausal symptoms receive treatment, despite that they perfectly fit the patient's profile for such therapy.All types of MHT are characterized by following effects: a positive effect on the cardiovascular system if MHT was start before 60 ages or in the first 10 years after menopause onset; the mortality rate from all causes is not increased in patients on MHT. The “ideal” MHT should relieve vasomotor symptoms, influence urogenital symptoms, prevent fractures and bone loss, protect the cardiovascular system and endometrium, and should not increase the risks of breast cancer, deep vein thrombosis and pulmonary embolism. Estradiol + dydrogesterone (Femoston®) scheme fits perfectly into these criteria. Femoston® is an oral MHT preparation that is effective in relieving symptoms of estrogen deficiency with a proven safety profile on the cardiovascular system and breast. This drug helps to reduce the manifestations of symptoms of estrogen deficiency, increase bone mineral density, and has a positive effect on metabolic processes. Numerous studies have shown that combination of estradiol + dydrogesterone is not only highly effective against menopausal symptoms, but also extremely important features, in particular, a proven safety profile for breast cancer.Keywords
This publication has 10 references indexed in Scilit:
- Breast Cancer Risk in Postmenopausal Women Using Estradiol–Progestogen TherapyObstetrics & Gynecology, 2009
- Risk of cardiovascular outcomes in users of estradiol/dydrogesterone or other HRT preparationsClimacteric, 2009
- Reprint of Classification and pharmacology of progestinsMaturitas, 2008
- Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort studyBreast Cancer Research and Treatment, 2007
- Hormone Therapy and Venous Thromboembolism Among Postmenopausal WomenJournal of the American College of Cardiology, 2007
- Clinical study comparing the effects of sequential hormone replacement therapy with oestradiol/dydrogesterone and conjugated equine oestrogen/norgestrel on lipids and symptomsArchiv für Gynäkologie, 2006
- Benign Breast DisordersThe New England Journal of Medicine, 2005
- Effects of low and high dose oestradiol and dydrogesterone therapy on insulin and lipoprotein metabolism in healthy postmenopausal womenClinical Endocrinology, 2004
- Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled TrialJAMA, 2002
- The Prevention of Osteoporosis Using Sequential Low-Dose Hormone Replacement Therapy with Estradiol-17β and DydrogesteroneOsteoporosis International, 2001